Nonpeptidic endothelin-converting enzyme inhibitors and their potential therapeutic applications

Canadian Journal of Physiology and Pharmacology

Volumn 80, Issue 5, 2002, Pages 440-449

  Jeng, Arco Y ^a   Mulder, Paul ^a   Kwan, Aij Lie ^a   Battistini, Bruno ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

CGS 26303; CGS 35066; ECE; Endothelin converting enzyme; FR 901533; Inhibitors; Metalloprotease; Phosphoramidon; SCH 54470

Indexed keywords

2 (4 BIPHENYLYL) 1 (1H TETRAZOL 5 YL)ETHYLAMINOMETHYLPHOSPHONIC ACID; 2 [3 [1 (2 CARBOXY 4 PHENYLBUTYL)CYCLOPENTANECARBOXAMIDO] 2,3,4,5 TETRAHYDRO 2 OXO 1H 1 BENZAZEPIN 1 YL]ACETIC ACID; 5,6,8,13 TETRAHYDRO 1,6,9,14 TETRAHYDROXY 3 (2 HYDROXYPROPYL) 7 METHOXY 8,13 DIOXOBENZO[A]NAPHTHACENE 2 CARBOXYLIC ACID; AUTACOID; B 90063; CGS 26582; CGS 34043; CGS 35066; DAGLUTRIL; DIBENZOFURAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENKEPHALINASE INHIBITOR; FR 901532; ISOENZYME; METALLOPROTEINASE; PD 069185; PHOSPHONAMIDE; PHOSPHORAMIDIC ACID; PHOSPHORAMIDON; PRODRUG; SA 6817; SCH 54470; SM 19712; UNCLASSIFIED DRUG; UNINDEXED DRUG; WS 75624B;

AMINO ACID SEQUENCE; BRAIN VASOSPASM; CARDIOVASCULAR DISEASE; CATALYSIS; CENTRAL NERVOUS SYSTEM DISEASE; CONFERENCE PAPER; DRUG EFFECT; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; HEART FAILURE; HUMAN; HYPERTENSION; IC 50; KIDNEY DISEASE; KIDNEY FAILURE; LUNG DISEASE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; RESTENOSIS; SEQUENCE HOMOLOGY; VASOCONSTRICTION;

ANIMALS; ASPARTIC ENDOPEPTIDASES; CARDIOVASCULAR DISEASES; ENZYME INHIBITORS; HUMANS; KIDNEY DISEASES; METALLOENDOPEPTIDASES; NERVOUS SYSTEM DISEASES;

EID: 0036099334     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y02-025     Document Type: Conference Paper

References (55)

1. Novel selective quinazoline inhibitors of endothelin converting enzyme-1
2. Endothelin-converting enzyme inhibitors and their effects
3. Effects of endothelins: Endothelin-induced responses in the pulmonary system
4. A receptor antagonist and phosphoramidon in renal ischemia
5. Systemic administration of an inhibitor of endothelin-converting enzyme for attenuation of cerebral vasospasm following experimental subarachnoid hemorrhage
6. Identity of endothelin-converting enzyme and other targets for the therapeutic regulation of endothelin biosynthesis
7. Pharmacological profile of a non-peptidic dual inhibitor of neutral endopeptidase 24.11 and endothelin-converting enzyme
8. Endothelin receptor antagonists
9. Attenuation of puromycin aminonucleoside-induced glomerular lesions in rats by CGS 26303, a dual neutral endopeptidase/endothelin-converting enzyme inhibitor
10. The clinical potential of endothelin receptor antagonists in cardiovascular medicine
11. The properties of enzyme inhibition by a novel dual inhibitor, SA6817, of neutral endopeptidase and angiotensin-converting enzyme
12. Aminophosphonate endothelin converting enzyme inhibitors: Potency-enhancing and selectivity-improving modifications of phosphoramidon
13. Role of endothelin-1 and big endothelin-1 in modulating coronary vascular tone, contractile function and severity of ischemia in rat hearts
14. Purification of a novel endothelin-converting enzyme specific for big endothelin-3
15. Therapeutic potential of endothelin converting enzyme inhibitors
16. Endothelin converting enzyme inhibitors
17. Design and synthesis of a potent and selective endothelin-converting enzyme inhibitor. CGS 35066
18. Endothelin system: The double-edged sword in health and disease
19. Endothelin-converting enzyme: Substrate specificity and inhibition by novel analogs of phosphoramidon
20. Blockade of endothelin-converting enzyme reduces pulmonary hypertension after cardiopulmonary bypass and circulatory arrest
21. Endothelins in the normal and diseased kidney
22. Benzofused macrocyclic lactams as triple inhibitors of endothelin-converting enzyme, neutral endopeptidase 24.11, and angiotensin-converting enzyme
23. Differential structure-activity relationships of phosphoramidon analogues for inhibition of three metalloproteases: Endothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting enzyme
24. Prevention and reversal of cerebral vasospasm by an endothelin-converting enzyme inhibitor, CGS 26303, in an experimental model of subarachnoid hemorrhage
25. A receptor blockade in chronic heart failure patients treated with ACE inhibitors
26. Effect of a highly selective endothelin-converting enzyme inhibitor on cardiac remodeling in rats after myocardial infarction
27. Phosphoramidon prevents cerebral vasospasm following subarachnoid hemorrhage in dogs: The relationship to endothelin-1 levels in the cerebrospinal fluid
28. Protective effect of SM-19712, a novel and potent endothelin converting enzyme inhibitor, on ischemic acute renal failure in rats
29. Design and synthesis of phosphinic acids that triply inhibit endothelin converting enzyme, angiotensin converting enzyme and neutral endopeptidase 24.11
30. Effect of phosphoramidon (endothelin converting enzyme inhibitor) and BQ-123 (endothelin receptor subtype A antagonist) on blood pressure in hypertensive rats
31. In-vivo results with SLV 306, an orally active inhibitor of NEP and ECE
32. Pharmacology of the active metabolite of SLV 306 - A mixed inhibitor of NEP and ECE
33. Endothelin-converting enzyme expression in the rat vascular injury model and human coronary atherosclerosis
34. Endothelin in hypertension: A role for receptor antagonists?
35. Chronic dual ECE-NEP inhibition with CGS 26303 improves cardiac hemodynamics and remodeling in rats with chronic heart failure
36. Modulation of tachykinins and bradykinin by enkephalinase
37. Isolation of an alternative spliced variant of bovine ECE-2
38. Therapeutic potential of endothelin receptor antagonists in cerebrovascular disease
39. Inhibition of endothelin-converting enzyme for protection against neointimal proliferation following balloon angioplasty of the rat carotid artery
40. Endothelins: Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology
41. Molecular characterization of human and bovine endothelin converting enzyme (ECE-1)
42. Identification of protease 3.4.24.11 as the major atrial natriuretic factor degrading enzyme in the rat kidney
43. Inhibition of big ET-1-induced pressor response by an orally active dual inhibitor of endothelin-converting enzyme and neutral endopeptidase 24.11
44. CGS 34043: A non-peptidic, potent and long-acting dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11
45. WS79089 A, B and C, new endothelin converting enzyme inhibitors isolated from Streptosporangium roseum. No. 79089. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities
46. WS75624 A and B, new endothelin converting enzyme inhibitors isolated from Saccharothrix sp. No. 75624. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities
47. Pharmacological characterization of a novel sulfonylureid-pyrazole derivative, SM-19712, a potent nonpeptidic inhibitor of endothelin converting enzyme
48. Attenuation of ischemic acute renal failure by phosphoramidon in rats
49. Disparate effects of phosphoramidon on blood pressure in SHR and DOCA-salt hypertensive rats
50. Renal effects of SCH 54470: A triple inhibitor of ECE, ACE, and NEP
51. Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure. Comparison of effects with those of endothelin A receptor antagonism
52. Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development
53. A novel potent vasoconstrictor peptide produced by vascular endothelial cells